Assessing the Clinical Potential for Immunotherapies in the Treatment of Breast Cancer

Release Date: February 22, 2016
Expiration Date: February 22, 2017
Media: Print with online posttest, evaluation, and request for credit


This  activity is designed to inform physicians about the  latest treatment advances in early-stage and  metastatic breast cancer, including approved and  investigational management strategies.

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This  activity is directed toward medical oncologists, primary care physicians, nurses, and  nurse practitioners who treat  patients with breast cancer. Surgical oncologists, radiation oncologists, pathologists, gynecologists, fellows, physician assistants, and  other healthcare providers interested in the  management of breast cancer are also invited to participate.

Learning Objectives

After participating in this  CME activity, learners should be better prepared to:

  • Explain the rationale and appropriate place for vaccines in the treatment of breast cancer
  • Discuss the role of checkpoint blockade in the  treatment of breast cancer
  • Summarize data from recent trials of vaccines and immunotherapies in breast cancer
  • Describe some of the combination therapies currently being studied in breast cancer
  • Discuss issues involved in matching patients with  appropriate treatments for breast cancer

The American Journal of Hematology/ Oncology® Editorial Board

Debu Tripathy, MD
Professor of Medicine and  Chair
Department of Breast Medical Oncology
The  University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and  Novartis.


Elizabeth Mittendorf, MD, PhD
Associate Professor
Department of Breast Surgical Oncology
The  University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support: Galena Biopharma and Antigen Express (institution receives funding)

Accreditation/Designation of Credit Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the  activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This continuing medical and nursing  education activity may or may not  discuss investigational, unapproved, or off-label uses of drugs. Participants are  advised to consult prescribing information for any products discussed. The information provided in this  CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the  independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the  content are  solely those of the  individual faculty members and do not  reflect those of Physicians' Education Resource®, LLC. Contact information for questions about the  activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By